Cagrilintide
Also known as: AM833
Cagrilintide is a catalog-expanded peptide entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, explicit_target_list, local_seed, project_target, seed corpus peptides, wiki_glp1, wikipedia_table. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Long-acting amylin analog. Investigational — Phase 3 trials ongoing, often co-administered with Semaglutide (CagriSema). Dose range reflects published trial protocols.
No cycle range recorded.
Limited published titration guidance outside trial protocols.
Contraindications
- • Severe gastroparesis
- • History of hypersensitivity to amylin analogs
Common side effects
- • Nausea
- • Vomiting
- • Decreased appetite
- • Injection site reactions
Serious risks
- • Long-term safety not established
- • Additive GI toxicity when combined with GLP-1 agonists
Drug interactions
- • Delays gastric emptying
Requires monitoring
- • HbA1c if diabetic
- • Weight
Pregnancy / breastfeeding
Contraindicated — investigational
- Not FDA approved — trial-stage compound
- Effective primarily in combination with GLP-1 agonists — monotherapy effect is smaller
- GI side effects are additive when combined with GLP-1 agonists — titrate slowly
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.